Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

On an adjusted basis, Regeneron earned $8.22 per share in the first quarter, below the average analyst estimate of $8.82, ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the ...